Safety and Efficacy Evaluation for an Ex Vivo Selection Free CRISPR/Cas9 Based Gene Therapy for HAX1 Associated Congenital Neutropenia

被引:0
|
作者
Ritter, Malte Ulrich [1 ]
Nasri, Masoud [1 ]
Dannenmann, Benjamin [1 ]
Kaufmann, Masako Monika [2 ]
Zeidler, Karl Alexander [3 ]
Secker, Benjamin [1 ]
Amend, Diana [1 ]
Haaf, Jeremy [1 ]
Zeidler, Cornelia [4 ]
Kliminakou, Maksim [1 ]
Cathomen, Toni [2 ]
Welte, Karl Heinirch [5 ]
Skokowa, Julia [1 ]
机构
[1] Univ Klinikum Tuebingen, Translat Onkol, Innere Med 2, Tubingen, Germany
[2] Univ Freiburg Klinikum, Inst Transfus Med & Gene Therapy, Freiburg, Germany
[3] Univ Klinikum Tuebingen, Allgemeine Padiatrie Haematol & Onkol, Kinderheilkunde 1, Tubingen, Germany
[4] Hannover Med Sch, Abt Mol Hamatopoese, Klin Padiat Hamatol & Onkol, Hannover, Germany
[5] Univ Klinikum Tuebingen, Mol Haematopoese, Kinderheilkunde 1, Tubingen, Germany
关键词
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
361
引用
收藏
页码:172 / 172
页数:1
相关论文
共 21 条
  • [1] A selection free ex vivo gene therapy approach to congenital neutropenia causing HAX1 mutations
    Ritter, M. U.
    Nasri, M.
    Dannenmann, B.
    Kaufmann, M. M.
    Zeidler, K. A.
    Zeidler, C.
    Klimiankou, M.
    Cathomen, T.
    Welte, K.
    Skokowa, J.
    KLINISCHE PADIATRIE, 2022, 234 (03): : 187 - 187
  • [2] Efficient Correction of HAX1 Mutations in Primary HSPCs of Severe Congenital Neutropenia Patients Using CRISPR/CAS9 GENE-Editing
    Ritter, Malte U.
    Secker, Benjamin
    Nasri, Masoud
    Klimiankou, Maksim
    Dannenmann, Benjamin
    Amend, Diana
    Haaf, Jeremy
    Mir, Perihan
    Bernhard, Regine
    Steiert, Ingeborg
    Zeidler, Cornelia
    Welte, Karl
    Skokowa, Julia
    BLOOD, 2020, 136
  • [3] A selection free Ex vivo gene therapy approach for curing the congenital neutropenia causing HAX1 p.W44X mutation
    Ritter, M. U.
    Nasri, M.
    Zeidler, K. A.
    Secker, B.
    Dannenmann, B.
    Amend, D.
    Haaf, J.
    Bernhard, R.
    Steiert, I
    Klimiankou, M.
    Zeidler, C.
    Welte, K. H.
    Skokowa, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 9 - 9
  • [4] CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
    Xiaohui Zhang
    Liren Wang
    Mingyao Liu
    Dali Li
    Science China Life Sciences, 2017, 60 : 468 - 475
  • [5] CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
    Xiaohui Zhang
    Liren Wang
    Mingyao Liu
    Dali Li
    Science China(Life Sciences), 2017, 60 (05) : 468 - 475
  • [6] CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
    Xiaohui Zhang
    Liren Wang
    Mingyao Liu
    Dali Li
    Science China(Life Sciences), 2017, (05) : 468 - 475
  • [7] CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy
    Zhang, Xiaohui
    Wang, Liren
    Liu, Mingyao
    Li, Dali
    SCIENCE CHINA-LIFE SCIENCES, 2017, 60 (05) : 468 - 475
  • [8] A Potential CRISPR/Cas9-Based Gene Therapy for Severe Congenital Neutropenia
    Ngoc Tung Tran
    Van Trung Chu
    Kuehn, Ralf
    Rajewsky, Klaus
    MOLECULAR THERAPY, 2019, 27 (04) : 309 - 310
  • [9] Gene Therapy Approach for Severe Congenital Neutropenia by CRISPR/Cas9 Gene-Editing of Hematopoietic Stem Cells and iPSCs
    Skokowa, Julia
    Ritter, Malte
    Nasri, Masoud
    Mir, Perihan
    Dannenmann, Benjamin
    Klimiankou, Maksim
    Aghaallaei, Nargessadat
    Secker, Benjamin
    Haaf, Jeremy
    Bravo, Natalia Alejandra Borbaran
    Zeidler, Cornelia
    Bajoghli, Baubak
    Xu, Yun
    Welte, Karl
    MOLECULAR THERAPY, 2020, 28 (04) : 166 - 167
  • [10] A comparison of different strategies for CRISPR/Cas9-based gene therapies of congenital neutropenia associated with ELANE mutations
    Ritter, M. U.
    Nasri, M.
    Dannenmann, B.
    Mir, P.
    Secker, B.
    Zeidler, C.
    Klimiankou, M.
    Welte, K.
    Skokowa, J.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A175 - A175